09:00 a.m.

10:30 a.m.

•

•

•

Academic session 2

Emerging therapies

Chair: J. Kastelein (The Netherlands)

Estrogens in vascular biology and disease:
where do we stand today?

J.-F. Arnal (France)

Statins in type 2 diabetes with renal insufficiency

R. Carmena (Spain)

New therapies for reverse cholesterol modulation in

metabolic diseases

B. Brewer (USA)

10:30 a.m.

11:00 a.m.

Coffee Break

11:00 a.m.

12:30 p.m.

•

•

SYMPOSIUM sponsored by ASTRAZENECA

The unaware coronary patient: 2 clinical cases

Chairs: J.-C. Fruchart (France), E. Bruckert (France)

The diabetic patient

M. Krempf (France), S. Kownator (France),
E. Bruckert (France)

The arteritic patient

M. Krempf (France), S. Kownator (France),
E. Bruckert (France)

12:30 p.m.

02:00 p.m.

•

•

Lunch Debate sponsored by SANOFI-AVENTIS

Cardiometabolic risk in diabetes

Title to be defined

G. Charpentier (France)

Title to be defined

P. James (UK)

02:00 p.m.

04:00 p.m.

•

•

•

•

FONDATION COEUR ET ARTERES - Symposium 2

Is there an impact of the pleiotropic effects

of lipid lowering drugs in the treatment of the

metabolic syndrome?

Chairs: M.-R. Taskinen (Finland) - E.-J. Schaefer (USA)

Is LDL-cholesterol lowering necessary in the management of the cardiovascular risk in the metabolic syndrome?

J. Betteridge (UK)

Are pleiotropic effects of statins clinically significant?

J. Davignon (Canada)

Vascular effects of PPARalpha and PPARgamma
activators - from bench to bedside

N. Marx (Germany)

What parts of pleiotropic actions of statins are mediated by Peroxisome Proliferators-Activated Receptors?

P. Duriez (France)

04:00 p.m.

04:30 p.m.

Coffee Break

04:30 p.m.

06:00 p.m.

•

•

•

•

•

SYMPOSIUM sponsored by TAKEDA

The type 2 diabetic patient, the updated situation or what is really new?

Chair : G. Charpentier (France)

The diabetes physiopatology, from insulinoresistance
to type 2 Diabetes

A. Avignon (France)

Glitazones, which treatment for who?

G. Charpentier (France)

The DB2 lipids, the 2008 updates

B. Staels (France)

Glitazones et metaanalyses

M. A. Lincoff (USA)

What should we think about heart and glitazones in 2008 ?

A. Cohen Solal (France)